AstraZeneca’s heart drug Wainua fails late-stage trial, raising 2027 outlook concerns

AstraZeneca announced that its experimental heart disease therapy, Wainua, did not meet primary endpoints in a Phase III trial conducted in July.

The failure is a setback for the company, whose pipeline has been praised, and puts pressure on upcoming data and product launches slated for 2027.

CEO Pascal Soriot acknowledged the disappointment and said the company will review the data and consider next steps.

Analysts note that the miss could affect investor sentiment and may shift focus to other late-stage candidates in the portfolio.